Clinical Trials
2 trialsNCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04976634 2025-04-06
MK-6482-016
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting